Tag: KMU Innovativ
Company News: Scil Technology Receives Public Research Grant for Novel Rheumatoid Arthritis Treatments
Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF’s KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology’s research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).
The course of RA is affected by the destruction of cartilage tissue and inflammation of the joints. Recently, it has been published that so-called repellent proteins inhibit fundamental processes relevant for the development of the disease. Repellent proteins therefore bear the potential to provide the first causative treatment of RA.